share_log

晶泰控股-P:截至2024年12月31日止年度的年度業績公告

XTALPI-P: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024

HKEX ·  Mar 28 09:57

Summary by Moomoo AI

晶泰控股2024年實現營業收入人民幣266.4百萬元,同比增長52.8%;經調整淨虧損收窄12.5%至456.8百萬元人民幣。公司已提前達成聯交所對已商業化公司的收入門檻要求(250百萬港元)。通過實施「AI+高效經營策略」,月均現金消耗同比下降22.6%至48.1百萬元人民幣。在業務進展方面,公司的機器人實驗室已覆蓋80%以上常見藥化反應類型,每月可積累20萬條以上反應過程數據。2024年新建20多種AI反應性預測模型,準確率均超過80%。與強生、優時比等跨國藥企達成商業授權協議,獲得頂尖藥企認可。與希格生科合作開發的全球首個瀰漫型胃癌靶向候選藥物獲得FDA快速通道認定。展望未來,公司將持續迭代自主創新的AI+機器人基礎設施,積極推動高柔性高精度自主機器人實驗室的打造。2025年第一季度已完成兩次配售,募集資金淨額約31.25億港元。基於目前現金儲備及募資所得,預計可維持未來約十年的運營需求。
晶泰控股2024年實現營業收入人民幣266.4百萬元,同比增長52.8%;經調整淨虧損收窄12.5%至456.8百萬元人民幣。公司已提前達成聯交所對已商業化公司的收入門檻要求(250百萬港元)。通過實施「AI+高效經營策略」,月均現金消耗同比下降22.6%至48.1百萬元人民幣。在業務進展方面,公司的機器人實驗室已覆蓋80%以上常見藥化反應類型,每月可積累20萬條以上反應過程數據。2024年新建20多種AI反應性預測模型,準確率均超過80%。與強生、優時比等跨國藥企達成商業授權協議,獲得頂尖藥企認可。與希格生科合作開發的全球首個瀰漫型胃癌靶向候選藥物獲得FDA快速通道認定。展望未來,公司將持續迭代自主創新的AI+機器人基礎設施,積極推動高柔性高精度自主機器人實驗室的打造。2025年第一季度已完成兩次配售,募集資金淨額約31.25億港元。基於目前現金儲備及募資所得,預計可維持未來約十年的運營需求。
In 2024, Jingtai Holdings achieved a revenue of 266.4 million yuan, a year-on-year increase of 52.8%; the adjusted net loss narrowed by 12.5% to 456.8 million yuan. The company has met the revenue threshold requirement for commercialized companies set by the Stock Exchange in advance (250 million Hong Kong dollars). By implementing the "AI + Efficient Operation strategy", the average monthly cash consumption decreased by 22.6% year-on-year to 48.1 million yuan.In terms of business progress, the company's Siasun Robot&Automation laboratory has covered over 80% of common pharmaceutical reaction types, accumulating more than 0.2 million pieces of reaction process data per month. In 2024, more than 20 new AI reactive prediction models were established, with an accuracy rate exceeding 80%. Business licensing agreements have been reached with multinational...Show More
In 2024, Jingtai Holdings achieved a revenue of 266.4 million yuan, a year-on-year increase of 52.8%; the adjusted net loss narrowed by 12.5% to 456.8 million yuan. The company has met the revenue threshold requirement for commercialized companies set by the Stock Exchange in advance (250 million Hong Kong dollars). By implementing the "AI + Efficient Operation strategy", the average monthly cash consumption decreased by 22.6% year-on-year to 48.1 million yuan.In terms of business progress, the company's Siasun Robot&Automation laboratory has covered over 80% of common pharmaceutical reaction types, accumulating more than 0.2 million pieces of reaction process data per month. In 2024, more than 20 new AI reactive prediction models were established, with an accuracy rate exceeding 80%. Business licensing agreements have been reached with multinational pharmaceutical companies such as Johnson & Johnson and UCB, earning recognition from top pharmaceutical companies. The world's first targeted candidate drug for diffuse gastric cancer developed in collaboration with Higea Bio has received FDA Fast Track designation.Looking ahead, the company will continue to iterate on its independently innovative AI + Robot infrastructure and actively promote the development of high-flexibility, high-precision autonomous robot laboratories. In the first quarter of 2025, two placements have been completed, raising a net amount of approximately 3.125 billion Hong Kong dollars. Based on the current cash reserves and fundraising proceeds, it is expected to maintain future operational needs for about ten years.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 393

Recommended

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.